Inhibrx Biosciences INBX
NASDAQ INBX
$98.86 +3.56 (+3.74%)
As of: Oct 21, 2026 · 2:45 PM EDT

Inhibrx Biosciences (INBX) EBT (2023 - 2026)

Updated

Inhibrx Biosciences (INBX) reported EBT of -$36.65 million for Q2 2026, compared with -$28.65 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) EBT (2023 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Inhibrx Biosciences' EBT came in at -$133.39 million; for FY2025, it came in at -$140.05 million.

  • By year, EBT came in at $1.69 billion in FY2024 and -$239.72 million in FY2023.
  • The Q2 2026 figure ranks as the lowest quarterly EBT since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT (Qtr)
1 Eli Lilly 1,136.71 Bn 1,105.29 Bn 19.71 Bn 9.25 Bn
2 Johnson & Johnson 617.55 Bn 536.07 Bn 17.26 Bn 6.75 Bn
3 AbbVie 501.02 Bn 474.13 Bn 12.70 Bn 4.28 Bn
4 Merck 368.18 Bn 322.56 Bn 12.21 Bn -683.00 Mn
5 Novartis Ag 297.89 Bn 261.88 Bn 11.24 Bn 4.27 Bn
6 Astrazeneca 261.33 Bn 235.02 Bn 12.86 Bn 2.80 Bn
7 Amgen 236.60 Bn 191.99 Bn 7.24 Bn 2.77 Bn
8 Gilead Sciences 190.55 Bn 164.75 Bn 6.22 Bn -10.25 Bn
9 Pfizer 169.77 Bn 116.42 Bn 10.94 Bn -653.00 Mn
10 Inhibrx Biosciences 1.55 Bn 951.77 Mn - -36.65 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -36.65 Mn
Dec 31, 2025 -32.83 Mn
Sep 30, 2025 -35.26 Mn
Jun 30, 2025 -28.65 Mn
Mar 31, 2025 -43.31 Mn
Dec 31, 2024 -47.87 Mn
Sep 30, 2024 -43.86 Mn
Jun 30, 2024 1.86 Bn
Mar 31, 2024 -78.71 Mn
Dec 31, 2023 -91.97 Mn
Sep 30, 2023 -51.79 Mn
Jun 30, 2023 -47.05 Mn
API Access

Inhibrx Biosciences EBT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebt&ticker=INBX&period=max&api_key=YOUR_API_KEY